Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Paton

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Journal of Psychopharmacology (Oxford, England)|May 22, 2010
Lithium in bipolar and other affective disorders: prescribing practice in the UKCarol Paton, Thomas R E Barnes, Amber Shingleton-Smith, et al.
Bjpsych Open|July 31, 2025
Rapid tranquillisation for psychiatric in-patients with a diagnosis of personality disorder: under-recognised issueCarol Paton, Mike J Crawford, Matthew Hartley, et al.
Trials|July 19, 2015
Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluationMike J Crawford, Rahil Sanatinia, Barbara Barrett, et al.
Therapeutic Advances in Psychopharmacology|July 7, 2018
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trialThomas R E Barnes, Verity Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 5, 2017
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectivenessThomas Re Barnes, Verity C Leeson, Carol Paton, et al.
The American Journal of Psychiatry|April 7, 2018
The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled TrialMike J Crawford, Rahil Sanatinia, Barbara Barrett, et al.
Health Technology Assessment (Winchester, England)|April 14, 2018
Lamotrigine for people with borderline personality disorder: a RCTMike J Crawford, Rahil Sanatinia, Barbara Barrett, et al.
Health Technology Assessment (Winchester, England)|April 21, 2016
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trialThomas R E Barnes, Verity C Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 15, 2020
Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCTMichael J Crawford, Lavanya Thana, Rachel Evans, et al.
Therapeutic Advances in Psychopharmacology|May 5, 2022
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trialMike J Crawford, Verity C Leeson, Rachel Evans, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Journal of Psychopharmacology (Oxford, England)|May 22, 2010
Lithium in bipolar and other affective disorders: prescribing practice in the UKCarol Paton, Thomas R E Barnes, Amber Shingleton-Smith, et al.
Bjpsych Open|July 31, 2025
Rapid tranquillisation for psychiatric in-patients with a diagnosis of personality disorder: under-recognised issueCarol Paton, Mike J Crawford, Matthew Hartley, et al.
Trials|July 19, 2015
Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluationMike J Crawford, Rahil Sanatinia, Barbara Barrett, et al.
Therapeutic Advances in Psychopharmacology|July 7, 2018
Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trialThomas R E Barnes, Verity Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 5, 2017
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectivenessThomas Re Barnes, Verity C Leeson, Carol Paton, et al.
The American Journal of Psychiatry|April 7, 2018
The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled TrialMike J Crawford, Rahil Sanatinia, Barbara Barrett, et al.
Health Technology Assessment (Winchester, England)|April 14, 2018
Lamotrigine for people with borderline personality disorder: a RCTMike J Crawford, Rahil Sanatinia, Barbara Barrett, et al.
Health Technology Assessment (Winchester, England)|April 21, 2016
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trialThomas R E Barnes, Verity C Leeson, Carol Paton, et al.
Health Technology Assessment (Winchester, England)|September 15, 2020
Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCTMichael J Crawford, Lavanya Thana, Rachel Evans, et al.
Therapeutic Advances in Psychopharmacology|May 5, 2022
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trialMike J Crawford, Verity C Leeson, Rachel Evans, et al.
Pageof 7